Novartis Ag · SIX:NOVN
Novartis — Q4 2023 Earnings Presentation
86 slides from Novartis's earnings presentation, Jan 31, 2024
Slide 1: Q4 2023 Results
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Q4 2023 Results Q4 2023 Results Investor presentation Investor presentation January 31, 2024 January 31, 2024 Novartis Q4 Results | January 31, 2024 1
Slide 2: Disclaimer
Content Click below to navigate Disclaimer through the document Company overview Financial review This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potenti
Slide 3: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Company Appendix References Company overview overview Vas Narasimhan, M.D. Vas Narasimhan, M.D. Chief Executive Officer Chief Executive Officer Novartis Q4 Results | January 31, 2024 3
Slide 4: Strong full year performance with margin expansion and innovation momentum
Content Click below to navigate Novartis delivers strong full year performance with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts through the document Company overview Financial review Double-digit growth for sales and Core OpInc Several major innovation milest
Slide 5: Completed the transformation; laying the foundation for future growth
Content Click below to navigate Completed the transformation; laying the foundation for our future growth through the document Company overview Financial review Strategy Vx AH Conclusions OTC FY 2014 FY 2023 Appendix Pre-portfolio Alcon Focused Pure-play transformation company Innovative Innovative
Slide 6: Strong Q4 growth driven by Entresto, Kesimpta, Kisqali and Cosentyx
GROWTH Content Click below to navigate Strong Q4 growth driven by performance from Entresto®, Kesimpta®, Kisqali® and Cosentyx® through the document Company overview Financial review Q4 sales Conclusions Sales Growth vs. PY Growth vs. PY USD million USD million cc Appendix 1,635 344 26% 641 272 73%
Slide 7: Entresto delivers 31% FY growth; expecting USD 7bn peak sales
GROWTH Content Click below to navigate Entresto® delivers 31% FY growth with sales reaching USD 6bn. Expecting USD 7bn peak sales through the document Company overview Financial review Sales evolution US weekly TRx1 Continues strong momentum in Q4 USD m, % cc Total prescriptions (000) Conclusions FY
Slide 8: Cosentyx FY sales reached USD 5bn
GROWTH Content Click below to navigate Cosentyx® FY sales reached USD 5bn1. Expect mid to high single-digit growth in 2024 and USD 7bn peak sales through the document Company overview Financial review Sales evolution Q4 performance benefitted from lower PY base USD m, % cc Conclusions FY USD 5.0bn1
Slide 9: Kesimpta FY sales doubled to USD 2.2bn
GROWTH Content Click below to navigate Kesimpta® FY sales doubled (USD 2.2bn) and on track for USD 4bn peak based on compelling product profile through the document Company overview Financial review Sales evolution Launch momentum continues across all regions USD m, % cc Conclusions FY USD 2.2bn • >
Slide 10: Kisqali FY sales reached USD 2.1bn in mBC
GROWTH Content Click below to navigate Kisqali® FY sales reached USD 2.1bn in metastatic breast cancer (mBC). Maintain USD 4bn peak sales guidance for mBC through the document Company overview Financial review Sales evolution US mBC NBRx share1 Expect continued strong USD m, % cc Rolling 3 months, %
Slide 11: Pluvicto FY sales close to blockbuster; supply unconstrained
GROWTH Content Click below to navigate Pluvicto® FY sales close to blockbuster. Supply now unconstrained. Maintain multi-bn peak sales guidance for current indication (post-taxane) through the document Company overview ® Financial review Sales evolution USD m, % cc • Q4 sales grew YoY (+53% cc) and
Slide 12: Scemblix continues strong launch trajectory
GROWTH Content Click below to navigate Scemblix® continues strong launch trajectory, driven by increasing recognition of its differentiated profile and high unmet need in CML through the document Company overview Financial review Sales evolution USD m • FY and Q4 sales more than doubled driven by hi
Slide 13: Scemblix: ASC4FIRST trial met both primary endpoints
INNOVATION Content Click below to navigate Scemblix®: ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results through the document Company overview Financial review Both primary endpoints met Study design Primary Secondary End of Conclusions • Scem
Slide 14: Leqvio adoption continues to expand across regions
GROWTH Content Click below to navigate Leqvio® adoption continues to expand across regions through the document Company overview Financial review Sales evolution US: Steady growth, ahead of advanced lipid lowering market1 USD m, % cc Adoption Conclusions FY USD 355m US Ex-US +217% • 3,500 facilities
Slide 15: Fabhalta: FDA approved in PNH; positive early launch signals
GROWTH Content Click below to navigate Fabhalta®1: FDA approved with compelling label in PNH Positive early launch signals, expect modest ramp through the document Company overview Financial review Strong product profile reflected in label Conclusions Compelling data Broad population Oral administra
Slide 16: Achieved our innovation milestones in 2023
INNOVATION Content Click below to navigate Achieved our innovation milestones in 2023 10 positive Ph3 readouts for medicines with significant sales potential1 through the document Company overview Financial review Status update – as of end Q4 10 positive Ph3 readouts Conclusions Regulatory Cosentyx®
Slide 17: Iptacopan: Ph3 APPEAR study in C3G
INNOVATION Content Click below to navigate Iptacopan: Ph3 APPEAR study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3G through the document Company overview Financial review Ph2 showed sustained benefits up to 1 year Ph3 met primary endpoin
Slide 18: Iptacopan and atrasentan: positive Ph3 readouts in IgAN
INNOVATION Content Click below to navigate Iptacopan and atrasentan: Positive Ph3 readouts demonstrating clinically meaningful proteinuria reduction in IgAN through the document Company overview Financial review Assets 2021 2022 2023 2024 2025 2026+ Comments Conclusions Appendix Iptacopan Ph3 - APPL
Slide 19: Expect to continue our innovation momentum in 2024
INNOVATION Content Click below to navigate Expect to continue our innovation momentum in 2024... through the document Company overview Financial review 2024 selected key events (expected) H1 2024 H2 2024 Conclusions Regulatory Fabhalta® PNH EU, JP Appendix decisions Kisqali® HR+/HER2- adj.BC US, EU
Slide 20: >20 key submissions in core therapeutic areas by 2028
INNOVATION Content Click below to navigate ... and to deliver >20 key submissions in core therapeutic areas by 2028 through the document Company overview Financial review Select key assets submission schedule Conclusions Core therapeutic 2024 2025 2026-2028 Appendix areas atrasentan pelacarsen Cosen
Slide 21: Signed >15 strategic deals totaling >6bn USD
INNOVATION Content Click below to navigate We have signed >15 strategic deals during the last year, totaling >6bn USD, to enhance our pipeline across core therapeutic areas and technology platforms through the document Company overview Financial review Select recent examples Conclusions CRM Appendix
Slide 22: Updating mid-term sales guidance: +5% CAGR 2023-2028
Content Click below to navigate Updating mid-term sales guidance: Expect to grow +5% CAGR 2023-2028 and maintaining core margin of ~40%+ by 2027 through the document Company overview Financial review Conclusions Appendix References Novartis Q4 Results | January 31, 2024 22
Slide 23: Focus on material ESG factors
IMPACT Content Click below to navigate We continue to focus on material environmental, social and governance factors alongside our pursuit of sustainable shareholder value creation through the document Company overview Financial review Conclusions Value creation Risk mitigation Consistent Innovation
Slide 24: Financial review and 2024 guidance
Content Click below to navigate through the document Company overview Financial review Conclusions Financial review Appendix References Financial review and 2024 guidance and 2024 guidance Harry Kirsch Harry Kirsch Chief Financial Officer Chief Financial Officer Novartis Q4 Results | January 31, 202
Slide 25: Strong operational performance over a number of years
FINANCIAL PROFILE Content Click below to navigate Novartis continues to deliver strong operational performance over a number of years... through the document Company overview Financial review Continuing operations1 performance, numbers restated post-Sandoz spin-off Conclusions Net sales Core OpInc2
Slide 26: In 2023, met/exceeded upgraded FY guidance
FINANCIAL PROFILE Content Click below to navigate ... and in 2023, met/exceeded our upgraded FY guidance through the document Company overview Financial review Continuing operations1 Conclusions In cc Appendix FY guidance (Q3 Sales expected to grow high Core operating income expected References earn
Slide 27: Robust top and bottom-line growth during the quarter and FY
FINANCIAL PROFILE Content Click below to navigate Robust top and bottom-line growth during the quarter and FY through the document Company overview Financial review Continuing operations¹ Q4 Change vs. PY FY Change vs. PY Conclusions USD million 2023 % USD % cc 2023 % USD % cc Appendix Net sales 11,
Slide 28: Continuing to create significant shareholder value
FINANCIAL PROFILE Content Click below to navigate Continuing to create significant shareholder value through the document Company overview Financial review Investing in the business Returning capital to shareholders Conclusions Appendix Investments in organic business Consistently growing annual div
Slide 29: USD 28.6bn of value created since Sandoz spin-off
FINANCIAL PROFILE Content Click below to navigate For Novartis and Sandoz shareholders since October 3, 2023, USD 28.6bn (+13.9%) of value has been created through the document Company overview Financial review Market capitalization growth since the Sandoz spin-off Sandoz spin-off highlights Conclus
Slide 30: Proposed 3.30 CHF/share dividend; 27th consecutive increase
FINANCIAL PROFILE Content Click below to navigate Novartis proposes 3.30 CHF/share1 dividend at the AGM; 27th consecutive dividend increase (no rebasing post Sandoz spin-off) through the document Company overview Financial review 4.0 CHF dividend USD dividend4 Conclusions 3.5 2022: 2023 proposal: CH
Slide 31: 2024 full year guidance
FINANCIAL PROFILE Content Click below to navigate Novartis (continuing operations1) 2024 full year guidance Expected, barring unforeseen events; growth vs. PY in cc through the document Company overview Financial review Conclusions Net sales expected Core operating income FY 2024 guidance on Appendi
Slide 32: Expected currency impact for Q1 and full year 2024
FINANCIAL PROFILE Content Click below to navigate Expected currency impact for Q1 and full year 2024 through the document Company overview Financial review Conclusions Appendix References Novartis Q4 Results | January 31, 2024 32
Slide 33: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Conclusions Vas Narasimhan, M.D. Vas Narasimhan, M.D. Chief Executive Officer Chief Executive Officer Novartis Q4 Results | January 31, 2024 33
Slide 34: Very strong 2023; confident for 2024 and mid-term
Content Click below to navigate through the document Company overview Financial review Very strong 2023: Double-digit growth for sales and Core OpInc for the quarter and full year Conclusions Appendix References Met/exceeded all strategic, operational and innovation targets: Including successful San
Slide 35: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations References Appendix Appendix Novartis Q4 Results | January 31, 2024 35
Slide 36: Strong FY growth driven by Entresto, Kesimpta, Kisqali and Pluvicto
GROWTH Content Click below to navigate Strong FY growth driven by performance from Entresto®, Kesimpta®, Kisqali® and Pluvicto® through the document Company overview Financial review FY sales Conclusions Sales Growth vs. PY Growth vs. PY USD million USD million USD growth @ Period cc Appendix 6,035
Slide 37: Our pipeline projects at a glance
INNOVATION Content Click below to navigate Our pipeline projects at a glance through the document Company overview Financial review Phase 1/2 Phase 3 Registration Total Conclusions Oncology 25 12 3 40 Appendix Solid tumors 18 6 3 27 Innovation: Pipeline overview Hematology 7 6 0 13 Financial perform
Slide 38: Novartis pipeline in Phase 1
INNOVATION Content Click below to navigate Novartis pipeline in Phase 1 17 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) DFT383 DFT383 CTNS gene delivery Cystinosis pre/post kidney tran
Slide 39: Novartis pipeline in Phase 2
INNOVATION Content Click below to navigate Novartis pipeline in Phase 2 20 lead indications through the document Lead indication Company overview Oncology Immunology Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) Solid tumors CFZ533 iscalimab CD40 inhibitor Sjögren’s Financial r
Slide 40: Novartis pipeline in Phase 3
INNOVATION Content Click below to navigate Novartis pipeline in Phase 3 8 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) AMG334 Aimovig® CGRPR antagonist Migraine, pediatrics Solid tumor
Slide 41: Novartis pipeline in registration
INNOVATION Content Click below to navigate Novartis pipeline in registration through the document Company overview Oncology Code Name Mechanism Indication(s) Solid tumors Financial review LEE011 Kisqali® CDK4/6 Inhibitor HR+/HER2- BC (adj) INC424 Jakavi® JAK1/2 inhibitor Acute GVHD, pediatrics Chron
Slide 42: Novartis submission schedule: new molecular entities
INNOVATION Content Click below to navigate Novartis submission schedule New Molecular Entities: Lead and supplementary indications through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2024 2025 2026 ≥2027 Conclusions atrasentan pelacarsen ia
Slide 43: Submission schedule: existing brands
INNOVATION Content Click below to navigate Novartis submission schedule Supplementary indications for existing brands through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2024 2025 2026 ≥2027 Conclusions Lutathera® Cosentyx® Cosentyx® Aimovi
Slide 44: Net debt increased by USD 3.0bn
FINANCIAL PROFILE Content Click below to navigate Net debt increased by USD 3.0bn mainly due to dividends and share buybacks, partly offset by FCF through the document Company overview Financial review USDbn Conclusions -3.0 Appendix Innovation: Pipeline overview Financial performance Innovation: Cl
Slide 45: IR Clinical Studies
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N euroscience
Slide 46: IR Clinical Studies: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N
Slide 47: atrasentan - ETA receptor antagonist
Content Click below to navigate atrasentan - ETA receptor antagonist through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 380 Primary Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Slide 48: iptacopan - CFB inhibitor
Content Click below to navigate iptacopan - CFB inhibitor iptacopan - CFB inhibitor through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 49: iptacopan - CFB inhibitor
Content Click below to navigate iptacopan - CFB inhibitor iptacopan - CFB inhibitor through the document Company overview NCT03955445 (CLNP023B12001B) NCT04817618 APPEAR-C3G (CLNP023B12301) Financial review Indication C3 glomerulopathy (C3G) Indication C3 glomerulopathy Phase Phase 2 Phase Phase 3 C
Slide 50: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Hypercholesterolemia inc. Heterozygous Familial H
Slide 51: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT04652726 ORION-16 (CKJX839C12301) NCT04659863 ORION-13 (CKJX839C12302) Financial review Indication Hyperlipidemia, pediatrics Indication Hyperlipidemia
Slide 52: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) NCT05763875 V-Mono (CKJX839D12304) Financial review Indication CVRR (Primary prevention) Indication CVRR (Primary
Slide 53: pelacarsen - ASO targeting Lp(a)
Content Click below to navigate pelacarsen - Antisense oligonucleotide (ASO) through the document targeting Lp(a) Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 54: XXB750 - NPR1 agonist
Content Click below to navigate XXB750 - NPR1 agonist XXB750 - NPR1 agonist through the document Company overview NCT05562934 (CXXB750B12201) NCT06142383 (CXXB750A12201) Financial review Indication Hypertension Indication Heart failure Phase Phase 2b Phase Phase 2 Conclusions Patients 170 Patients 7
Slide 55: zigakibart - Anti-APRIL
Content Click below to navigate zigakibart - Anti-APRIL through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 292 Appendix Primary Change in proteinuria [ Time Frame: 40 weeks or approximately 9 months
Slide 56: IR Clinical Studies: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N euroscience > O ncology
Slide 57: Cosentyx - IL-17A inhibitor
Content Click below to navigate Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A inhibitor through the document Company overview NCT05767034 REPLENISH (CAIN457C22301) NCT04930094 GCAPTAIN (CAIN457R12301) Financial review Indication Polymyalgia rheumatica Indication Giant cell arteritis Phase Phase 3
Slide 58: Cosentyx - IL-17A inhibitor
Content Click below to navigate Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A inhibitor through the document Company overview NCT05722522 (CAIN457O12301) NCT05758415 (CAIN457O12302) Financial review Indication Rotator cuff tendinopathy Indication Rotator cuff tendinopathy Phase Phase 3 Phase Phase
Slide 59: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor through the document Company overview NCT03217422 AMBER (CVAY736B2201) NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Autoimmune hepatitis Indication Lupus Nephritis Phase Phase 2 Phase Phase
Slide 60: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor through the document Company overview NCT05349214 NEPTUNUS-2 (CVAY736A2302) NCT05350072 NEPTUNUS-1 (CVAY736A2301) Financial review Indication Sjögren’s syndrome Indication Sjögren’s syndrome Phase Phase 3 Phase
Slide 61: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor through the document Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication Systemic lupus erythematosus Indication Systemic lupus erythem
Slide 62: LNA043 - ANGPTL3 agonist
Content Click below to navigate LNA043 - ANGPTL3 agonist through the document Company overview NCT04864392 ONWARDS (CLNA043A12202) Financial review Indication Knee osteoarthritis Phase Phase 2 Conclusions Patients 550 Primary Change from baseline in the cartilage thickness of the medial compartment
Slide 63: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05030311 REMIX-1 (CLOU064A2301) NCT05032157 REMIX-2 (CLOU064A2302) Financial review Indication Chronic spontaneous urticaria Indication Chronic spontaneous urticaria Pha
Slide 64: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor through the document Company overview NCT05976243 (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 348 Primary 1. Proportion of participants with complete response in Total Fric Sco
Slide 65: IR Clinical Studies: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N euroscience > O ncolog
Slide 66: Mayzent - S1P1,5 receptor modulator
Content Click below to navigate Mayzent® - S1P1,5 receptor modulator through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple sclerosis, pediatrics Phase Phase 3 Conclusions Patients 180 Primary Annualized relapse rate (ARR) in target pediatric parti
Slide 67: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple sclerosis Indication Multiple sclerosis Phase Phase 3 Phase
Slide 68: Zolgensma - SMN1 gene replacement therapy
Content Click below to navigate Zolgensma® - SMN1 gene replacement therapy Zolgensma® - SMN1 gene replacement therapy through the document Company overview NCT05089656 STEER (COAV101B12301) NCT05386680 STRENGTH (COAV101B12302) Financial review Indication Spinal muscular atrophy (IT administration) I
Slide 69: IR Clinical Studies: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N euroscience > O ncology >
Slide 70: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor through the document Company overview NCT05653349 VAYHIT1 (CVAY736I12301) NCT05653219 VAYHIT2 (CVAY736Q12301) Financial review Indication 1L Immune Thrombocytopenia Indication 2L Immune Thrombocytopenia Phase P
Slide 71: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor through the document Company overview NCT05648968 VAYHIA (CVAY736O12301) Financial review Indication Warm autoimmune hemolytic anemia Phase Phase 3 Conclusions Patients 90 Primary Binary variable indicating whether a patient achieves a dur
Slide 72: iptacopan - CFB inhibitor
Content Click below to navigate iptacopan - CFB inhibitor through the document Company overview NCT04889430 APPELHUS (CLNP023F12301) Financial review Indication Atypical haemolytic uraemic syndrome Phase Phase 3 Conclusions Patients 50 Primary Percentage of participants with complete TMA response wi
Slide 73: opnurasib - KRAS inhibitor
Content Click below to navigate opnurasib - KRAS inhibitor through the document Company overview NCT05132075 KontRASt-02 (CJDQ443B12301) Financial review Indication Non-small cell lung cancer, 2/3L Phase Phase 3 Conclusions Patients 360 Primary Progression free survival (PFS) Appendix Outcome Innova
Slide 74: Pluvicto - Radioligand therapy target PSMA
Content Click below to navigate Pluvicto® - Radioligand therapy target PSMA Pluvicto® - Radioligand therapy target PSMA through the document Company overview NCT04689828 PSMAfore (CAAA617B12302) NCT04720157 PSMAddition (CAAA617C12301) Financial review Indication Metastatic castration-resistant prost
Slide 75: Rydapt - Multi-targeted kinase inhibitor
Content Click below to navigate Rydapt® - Multi-targeted kinase inhibitor through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 20 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 76: Scemblix - BCR-ABL inhibitor
Content Click below to navigate Scemblix® - BCR-ABL inhibitor through the document Company overview NCT04971226 ASC4FIRST (CABL001J12301) Financial review Indication Chronic myeloid leukemia, 1st line Phase Phase 3 Conclusions Patients 402 Primary Major Molecular Response (MMR) at week 48 Appendix O
Slide 77: TNO155 - SHP2 inhibitor
Content Click below to navigate TNO155 - SHP2 inhibitor through the document Company overview NCT03114319 (CTNO155X2101) Financial review Indication Solid tumors (single agent) Phase Phase 1 Conclusions Patients 255 Primary Number of participants with adverse events Appendix Outcome Number of partic
Slide 78: Vijoice - PI3Ki
Content Click below to navigate Vijoice® - PI3Ki through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 230 Primary Outcome Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and
Slide 79: IR Clinical Studies: Other
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Other > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N euroscience > O ncology > O t
Slide 80: Beovu - VEGF Inhibitor
Content Click below to navigate Beovu® - VEGF Inhibitor through the document Company overview NCT04278417 CONDOR (CRTH258D2301) Financial review Indication Diabetic retinopathy Phase Phase 3 Conclusions Patients 694 Primary Change from Baseline in BCVA Appendix Outcome Innovation: Pipeline overview
Slide 81: IR Clinical Studies: Global Health
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Global Health > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N euroscience > O ncolo
Slide 82: cipargamin - PfATP4 inhibitor
Content Click below to navigate cipargamin - PfATP4 inhibitor through the document Company overview NCT04675931 KARISMA (CKAE609B12201) Financial review Indication Malaria severe Phase Phase 2 Conclusions Patients 252 Primary Percentage of participants achieving at least 90% reduction in Plasmodium
Slide 83: Coartem - PGH-1 (artemisinin combination therapy)
Content Click below to navigate Coartem® - PGH-1 (artemisinin combination therapy) through the document Company overview NCT04300309 CALINA (CCOA566B2307) Financial review Indication Malaria, uncomplicated (<5kg patients) Phase Phase 3 Conclusions Patients 44 Primary Artemether Cmax Appendix Outcome
Slide 84: ganaplacide/lumefantrine - Non-artemisinin plasmodium falciparum inhibitor
Content Click below to navigate ganaplacide/lumefantrine - Non-artemisinin through the document plasmodium falciparum inhibitor Company overview NCT05842954 KALUMA (CKLU156A12301 ) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1500 Primary PCR-corrected adequa
Slide 85: Abbreviations
Content Abbreviations Click below to navigate through the document Abbreviations Company overview AI Auto-injector IgAN IgA nephropathy AIH Autoimmune hepatitis IPF Idiopathic pulmonary fibrosis Financial review aHUS atypical Hemolytic Uremic Syndrome ITP Immune thrombocytopenia ALL Acute lymphoblas
Slide 86: References
Content Click below to navigate References through the document Company overview Financial review Entresto® (slide 7 references) 1 IQVIA National Prescription Audit. Conclusions 2 Approved indications differ by geography. Examples include “indicated to reduce the risk of cardiovascular death and hos